Gene therapy watch: 100 patients tracked for Long-Term safety and tumor control
NCT ID NCT07503613
First seen Apr 02, 2026 · Last updated May 20, 2026 · Updated 8 times
Summary
This study follows about 100 people with vestibular schwannoma (a non-cancerous brain tumor) who previously received a gene therapy called AAVAnc80-antiVEGF. Researchers will monitor participants for years to check for late side effects and measure any changes in tumor size using MRI scans. The goal is to understand the long-term safety and whether the therapy helps control the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VESTIBULAR SCHWANNOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas Southwestern
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.